Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial.
Wei-Qing WangStephen C BainFang BianRui ChenSanaz GaberyShan HuangThomas Bo JensenBifen LuoGuoyue YuanYanqiu Wangnull nullPublished in: Diabetologia (2024)
Novo Nordisk A/S.